We have located links that may give you full text access.
Biodistribution and Safety of Human Multi-Chimeric Cells (HMCC) After Systemic Intraosseous and Intravenous Administration in the Experimental Mouse Model.
Stem Cells and Development 2024 March 7
Cellular therapies provide promising options for inducing tolerance in transplantation of solid organs, bone marrow, and vascularized composite allografts. However, novel tolerance-inducing protocols remain limited despite extensive research. We previously introduced and characterized a Human Multi-Chimeric Cell (HMCC) line, created through ex vivo fusion of human umbilical cord blood (UCB) cells derived from three unrelated donors. In this study, we assessed in vivo biodistribution and safety of HMCC in the NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mouse model. Twenty-four NSG mice were randomly assigned to four groups (n=6/group) and received intraosseous (IO.) or intravenous (IV.) injections of 0.6 x 106 donor UCB cells or fused HMCC: Group 1 - UCB (IO.), Group 2 - UCB (IV.), Group 3 - HMCC (IO.), and Group 4 - HMCC (IV.). Hematopoietic phenotype maintenance and presence of HLA class I antigens in the selected lymphoid and non-lymphoid organs were assessed by flow cytometry (FC). Weekly evaluation and magnetic resonance imaging (MRI) assessed HMCC safety. Comparative analysis of delivery routes revealed significant differences in HLA class I percentages for IO.: 1.83%±0.79%, vs. IV. delivery: 0.04%±0.01%, p<0.01, and hematopoietic stem cell markers percentages of CD3 (IO.: 1.41%±0.04%, vs. IV.: 0.07%±0.01%, p<0.05), and CD4 (IO.: 2.74%±0.31%, vs. IV.: 0.59%±0.11%, p<0.01). Biodistribution analysis after IO. delivery confirmed HMCC presence in lymphoid organs and negligible presence in non-lymphoid organs, except for lung (IO.: 0.19%±0.06%, vs. IV.: 6.33%±0.56%, p<0.0001). No evidence of tumorigenesis was observed by MRI at 90 days following IO. and IV. administration of HMCC. This study confirmed biodistribution and safety of HMCC therapy in the NSG mouse model, both following IO. and IV. administration. However, IO. delivery route confirmed higher efficacy of engraftment and safety profile, introducing HMCC as a novel cell-based therapeutic approach with promising clinical applications in solid organ, bone marrow, and VCA transplantation.
Full text links
Related Resources
Trending Papers
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Prevention and treatment of ischaemic and haemorrhagic stroke in people with diabetes mellitus: a focus on glucose control and comorbidities.Diabetologia 2024 April 17
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Eosinophilic Esophagitis: Clinical Pearls for Primary Care Providers and Gastroenterologists.Mayo Clinic Proceedings 2024 April
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app